Jefferies Financial Group Inc. Raises Stake in Insulet Corporation $PODD

Jefferies Financial Group Inc. grew its stake in shares of Insulet Corporation (NASDAQ:PODD) by 132.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,361 shares of the medical instruments supplier’s stock after purchasing an additional 7,602 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Insulet were worth $3,798,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Insulet by 1.0% during the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after purchasing an additional 87,845 shares during the period. Northern Trust Corp boosted its stake in shares of Insulet by 0.5% during the third quarter. Northern Trust Corp now owns 709,180 shares of the medical instruments supplier’s stock valued at $218,945,000 after purchasing an additional 3,618 shares during the period. Qube Research & Technologies Ltd boosted its stake in shares of Insulet by 37.3% during the third quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock valued at $177,324,000 after purchasing an additional 156,009 shares during the period. Nordea Investment Management AB boosted its stake in shares of Insulet by 35.0% during the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after purchasing an additional 142,922 shares during the period. Finally, Ameriprise Financial Inc. boosted its stake in shares of Insulet by 0.8% during the third quarter. Ameriprise Financial Inc. now owns 494,712 shares of the medical instruments supplier’s stock valued at $152,703,000 after purchasing an additional 4,057 shares during the period.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Stifel Nicolaus lowered their price objective on shares of Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. Bank of America lowered their price objective on shares of Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research note on Monday, May 18th. BTIG Research set a $235.00 price objective on shares of Insulet in a research note on Tuesday. Benchmark assumed coverage on shares of Insulet in a research note on Tuesday, May 12th. They issued a “buy” rating for the company. Finally, Evercore lowered their price objective on shares of Insulet from $240.00 to $200.00 in a research note on Thursday, May 7th. Twenty-one investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $253.87.

Insulet Stock Performance

PODD stock opened at $153.80 on Wednesday. The firm has a market cap of $10.65 billion, a price-to-earnings ratio of 35.77, a PEG ratio of 1.23 and a beta of 1.20. The firm has a 50-day simple moving average of $188.59 and a two-hundred day simple moving average of $248.51. Insulet Corporation has a one year low of $145.59 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts forecast that Insulet Corporation will post 6.43 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.